Subsequently, these researchers extended their findings that EGCG attenuated EGFR 2 (HER2) or/and EGFR 3 (HER3)-induced FASN overexpression in breast cancer cells through suppressing PI3K/Akt signaling (219). Here, ERBB2 is linked to breast cancer.